Zymeworks BC Inc [ZYME] stock is trading at $13.77, up 9.46%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ZYME shares have gain 4.79% over the last week, with a monthly amount drifted -15.31%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Zymeworks BC Inc [NASDAQ: ZYME] stock has seen the most recent analyst activity on December 16, 2024, when JP Morgan upgraded its rating to a Overweight but kept the price target unchanged to $18 for it. Previously, Leerink Partners upgraded its rating to Outperform on November 07, 2024, and elevated its price target to $25. On November 01, 2024, downgrade downgraded it’s rating to Equal Weight but maintained its price target of $12 on the stock. H.C. Wainwright reiterated its recommendation of a Neutral and reduced its price target to $8 on January 04, 2023. Jefferies upgraded its rating to Buy for this stock on December 20, 2022, and upped its price target to $11. In a note dated November 01, 2022, H.C. Wainwright downgraded an Neutral rating on this stock and revised its target price from $40 to $8.
Zymeworks BC Inc [ZYME] stock has fluctuated between $7.97 and $17.70 over the past year. Currently, Wall Street analysts expect the stock to reach $19.5 within the next 12 months. Zymeworks BC Inc [NASDAQ: ZYME] shares were valued at $13.77 at the most recent close of the market. An investor can expect a potential return of 41.61% based on the average ZYME price forecast.
Analyzing the ZYME fundamentals
Zymeworks BC Inc [NASDAQ:ZYME] reported sales of 62.20M for the trailing twelve months, which represents a drop of -3.07%. Gross Profit Margin for this corporation currently stands at -0.02% with Operating Profit Margin at -1.95%, Pretax Profit Margin comes in at -1.9%, and Net Profit Margin reading is -1.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.27 and Total Capital is 0.0. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of89.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.36 points at the first support level, and at 12.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.14, and for the 2nd resistance point, it is at 14.51.
Ratios To Look Out For
For context, Zymeworks BC Inc’s Current Ratio is 4.10. In addition, the Quick Ratio stands at 4.10 and the Cash Ratio stands at 0.0. Considering the valuation of this stock, the price to sales ratio is 15.33, the price to book ratio is 2.63.
Transactions by insiders
Recent insider trading involved Galbraith Kenneth, Chair & CEO, that happened on Jan 05 ’24 when 18198.0 shares were sold. Chair & CEO, Galbraith Kenneth completed a deal on Jan 08 ’24 to sell 5706.0 shares. Meanwhile, SVP & Chief Financial Officer Astle Christopher sold 4563.0 shares on Jan 05 ’24.
